Cargando…

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections

Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only avail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghannoum, Mahmoud, Arendrup, Maiken Cavling, Chaturvedi, Vishnu P., Lockhart, Shawn R., McCormick, Thomas S., Chaturvedi, Sudha, Berkow, Elizabeth L., Juneja, Deven, Tarai, Bansidhar, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559578/ https://www.ncbi.nlm.nih.gov/pubmed/32854252 http://dx.doi.org/10.3390/antibiotics9090539

Ejemplares similares

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
por: Sobel, R, et al.
Publicado: (2021)

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
por: Jallow, Sabelle, et al.
Publicado: (2021)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples
por: Marathe, Anuradha, et al.
Publicado: (2022)

1579. Multidrug-Resistant Candida auris Isolates From New York Hospitals and Healthcare Facilities Are Susceptible to Antifungal Combinations
por: O’Brien, Brittany, et al.
Publicado: (2019)

So Many Diagnostic Tests, So Little Time: Review and Preview of Candida auris Testing in Clinical and Public Health Laboratories
por: Dennis, Emily K., et al.
Publicado: (2021)

Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April–July 2020
por: Chowdhary, Anuradha, et al.
Publicado: (2020)

Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
por: Ostrowsky, Belinda, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection
por: Lepak, Alexander J, et al.
Publicado: (2017)

1275. Evaluation of in vitro activity of manogepix against multidrug-resistant and pan-resistant Candida auris from the New York Outbreak
por: Zhu, Yan Chun, et al.
Publicado: (2020)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Invasive aspergillosis in patients with severe COVID-19 pneumonia
por: Helleberg, Marie, et al.
Publicado: (2021)

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)

466. All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
por: Arendrup, Maiken Cavling, et al.
Publicado: (2015)

Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates
por: Arendrup, Maiken Cavling, et al.
Publicado: (2016)

Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates
por: Georgiou, Panagiota-Christina, et al.
Publicado: (2022)

Evaluation of mean monocyte volume in septicemia caused by Salmonella species
por: Kumar, Dilip, et al.
Publicado: (2018)

A High Frequency of Candida auris Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study
por: Rajni, Ekadashi, et al.
Publicado: (2021)

P498 Pneumocystis Jirovecii pneumonia: Clinical profile and diagnostic modalities
por: Tarai, P Bansidhar
Publicado: (2022)

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
por: Daraskevicius, Justinas, et al.
Publicado: (2022)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles
por: Jørgensen, René, et al.
Publicado: (2017)

Novel Trichoderma polysporum Strain for the Biocontrol of Pseudogymnoascus destructans, the Fungal Etiologic Agent of Bat White Nose Syndrome
por: Zhang, Tao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j72hfko441r7gre8e8uj8pgp8g